Siyi ZOU

Dr. Siyi ZOU

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 October 2021 in Journal of Experimental & Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
JLJiewei Lin
Jiewei Lin
SZShuyu Zhai
Shuyu Zhai
SZSiyi ZOU
Siyi ZOU
ZXZhiwei Xu
Zhiwei Xu
JZJun Zhang
Jun Zhang
BSBaiyong Shen
Baiyong Shen
Background: FLVCR1-AS1 is a key regulator of cancer progression. However, the biological functions and underlying molecular mechanisms of pancreatic cancer (PC) remain unknown. Methods: FLVCR1-AS1 expression levels in 77 PC tissues and matched non-tumor tissues were analyzed by qRT-PCR. Moreover, the role of FLVCR1-AS1 in PC cell proliferation, cell cycle, and migration was verified via functional in vitro and in vivo experiments. Further, the potential competitive endogenous RNA (ceRNA) network between FLVCR1-AS1 and KLF10, as well as FLVCR1-AS1 transcription levels, were investigated. Results: FLVCR1-AS1 expression was low in both PC tissues and PC cell lines, and FLVCR1-AS1 downregulation was associated with a worse prognosis in patients with PC. Functional experiments demonstrated that FLVCR1-AS1 overexpression significantly suppressed PC cell proliferation, cell cycle, and migration both in vitro and in vivo. Mechanistic investigations revealed that FLVCR1-AS1 acts as a ceRNA to sequester miR-513c-5p or miR-514b-5p from the sponging KLF10 mRNA, thereby relieving their suppressive effects on KLF10 expression. Additionally, FLVCR1-AS1 was shown to be a direct transcriptional target of KLF10. Conclusions: Our research suggests that FLVCR1-AS1 plays a tumor-suppressive role in PC by inhibiting proliferation, cell cycle, and migration through a positive feedback loop with KLF10, thereby providing a novel therapeutic strategy for PC treatment.

5 December 2025 in Pancreas
Verified
Journal Article
Open access
SZSiyi ZOU
Siyi ZOU
CWChenlei Wen
Chenlei Wen
FLFanlu Li
Fanlu Li
LJLingXi Jiang
LingXi Jiang
QTQiang Tian
Qiang Tian
QZQian Zhan
Qian Zhan
Background: Adjuvant chemotherapy (AC) provides an improved long-term survival chance for those with R0/R1 resection, following limited survival improvement space, as well as intolerable side effects. There is currently a gap in the use of macromolecule-targeted drugs (nimotuzumab) added to AC, so we developed this study. Materials and Methods: Resectable pancreatic cancers (RPC) were treated with surgery and postoperative chemotherapy with or without nimotuzumab. Demographic and clinical data were collected from the electronic medical records of Ruijin Hospital from May 2016 to July 2022. The primary efficacy endpoint was OS. Additional endpoints included disease-free survival (DFS) and adverse reactions (safety). Results: Thirty-six RPC patients who had received AC with nimotuzumab (study arm) or 55 patients who had conducted AC alone (control arm) treatment out of the 795 patients screened. The median age was 61 years. The Barthel score was 99. The study arm demonstrated a prolonged median overall survival (mOS) and median disease-free survival (mDFS) trend compared with the control arm (mOS, 45.1 mo vs. 28.1 mo; mDFS, 20.0 mo vs. 13.0 mo). In the further exploratory analyses of KRAS mutation and KRASG12D types, the study arm also showed a survival benefit trend (mOS, 44.6 mo vs. 25.0 mo, mDFS, 30.9 mo vs. 10.3 mo in KRAS mutation; mOS, 36.2 mo vs. 19.6 mo in KRASG12D type). R0 patients with KRASG12D, the survival benefit on DFS was significantly different (mDFS, 16.0 mo vs. 9.9 mo; P =0.022). For adverse events grade 3 or higher calculated, the highest incidence of adverse reactions was slightly hematologic abnormalities, such as anemia, leukopenia, etc., in both groups. No grade 4 or above adverse reactions were observed. Conclusions: By adding nimotuzumab to existing gemcitabine-based AC regimens, RPC patients would show a survival benefit trend with a satisfactory safety profile.